Cidara Therapeutics announced that it has received formal notice from The Nasdaq Stock Market stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CDTX:
- Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Cidara Therapeutics, WuXi XDC expand collaboration for CD73 program
- Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program
- Cidara, Melinta report FDA advisors recommend approval for rezafungin
- Cidara Soars on Advisory Committee Recommendation for Candida Treatment